Basecamp Research raises more in one round than in its first seven years combined

Basecamp has raised $225M since it was founded in London in 2019, and $140M of that came in this round, so about $85M covered the first seven years. The new money is roughly 1.6 times everything raised before it, and 62 percent of the company's lifetime capital.

What it buys, on the company's own account, is a new generation of EDEN models and a pipeline moving towards clinical development, beginning with in vivo cell therapy. That means reprogramming a patient's cells inside the body by pairing long designed DNA sequences with large serine recombinases that integrate them into the genome. The cost problem Basecamp names is manufacturing, which for today's cell therapies runs into hundreds of thousands of dollars per patient. Read that phrase as $200,000 to $500,000 and the whole round equals between 280 and 700 patients of current-generation production. The platform case is that treating inside the body removes the per-patient factory step.

Sixteen investors are named. Split evenly that is under $9M each, and the lead will have taken more than a sixteenth. Six of the sixteen are not conventional venture funds: the NATO Innovation Fund, the UK government's Sovereign AI Fund, the Rockefeller Foundation, King Philanthropies, NVIDIA and Anthropic's Anthology Fund.

The last two were involved before the round. Both are named as partners in building the Trillion Gene Atlas, alongside PacBio and Ultima Genomics. Neither release says whether cash moves between them for compute or model work. S32, which led, was founded by Bill Maris.

"We believe the future of medicine lies in reprogramming the body to repair itself. We design the models and the medicines to teach it how," said Glen Gowers, co-founder and chief executive. Andre Hoffmann, vice-chairman of Roche, invested personally and said that "Personalised, AI-designed therapeutics represent the next transformation of that journey."

The releases name a modality. They do not name a molecule, and they give no valuation, no lead candidate and no filing date. In my view the $140M is a bet on the dataset first and a drug second, because the Atlas was assembled through access and benefit-sharing partnerships in more than 30 countries across all seven continents. A rival cannot replicate those partnerships. The case against: "strong preclinical results across multiple modalities and disease areas" is Basecamp's own characterisation. Preclinical breadth in a press release has a poor record of surviving a first patient. I would drop the dataset view if the first disclosed pharma deal pays chiefly for model access at a modest upfront, since that would say buyers are pricing the software. Until some partner pays a disclosed sum, this round is the only external price on EDEN.